Ignite Creation Date:
2024-05-05 @ 5:13 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00418496
Status:
COMPLETED
Last Update Posted:
2017-02-20
First Post:
2007-01-02
Brief Title:
Interleukin-2 With Sorafenib BAY 43-9006 for Unresectable or Metastatic Clear Cell Renal Carcinoma RCC and Metastatic Melanoma
Sponsor:
Organization:
Ohio State University Comprehensive Cancer Center
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
17
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE1 |
Observational Models:
Time Perspective List:
Who Masked List: